Cascade Biotechnology INC.
Home
Announcements 2022
Complement Therapeutics General Overview
Complement Therapeutics Disease Indications
Pipeline
Alzheimer's disease
Schizophrenia
Multiple Sclerosis-Autoimmune
Neuromyelitis Optica-Autoimmune
Myasthenia Gravis-Autoimmune
Amyotrophic Lateral Sclerosis (ALS) Autoimmune
Age-Related Macular Degeneration
Paroxysmal Nocturnal Hemoglobinuria
Cutaneous Squamous Cell Carcinoma (cSCC)
Cardiac and Myocardial Ischemia
Atypical Hemolytic Uremic Syndrome (aHUS)
Technology
Staff Publications
Funding
Scientific Advisory Board (SAB)
Management
Images
Complement Depletion and Disease Models
Human C3-1496 Potential Immunogenicity
C3b Crystal Structure Allows Amino Acid Changes that Stabilize C3 (sC3)
sC3 Designed for Increased Catalytic Efficiency, Potency, Better pK Properties
sC3 Depletes Complement More Potently than CVF
sC3 is More Stable in Serum
sC3 Resists Degradation
sC3 Gene Therapy Strategy
sC3 Gene Therapy Sub-Retinal Injections of Viral Particles
sC3 Gene Therapy Coding Sequence and HEK293 Co-Transfection
sC3 Gene Therapy, Vector Design Completed, Lentivirus Synthesized, RPE Cells Infected
sC3 Cascade Intellectual Property
Gallery
What's Hot in Complement 2020-2021
Cascade Biotechnology INC.
Home
Announcements 2022
Complement Therapeutics General Overview
Complement Therapeutics Disease Indications
Pipeline
Alzheimer's disease
Schizophrenia
Multiple Sclerosis-Autoimmune
Neuromyelitis Optica-Autoimmune
Myasthenia Gravis-Autoimmune
Amyotrophic Lateral Sclerosis (ALS) Autoimmune
Age-Related Macular Degeneration
Paroxysmal Nocturnal Hemoglobinuria
Cutaneous Squamous Cell Carcinoma (cSCC)
Cardiac and Myocardial Ischemia
Atypical Hemolytic Uremic Syndrome (aHUS)
Technology
Staff Publications
Funding
Scientific Advisory Board (SAB)
Management
Images
Complement Depletion and Disease Models
Human C3-1496 Potential Immunogenicity
C3b Crystal Structure Allows Amino Acid Changes that Stabilize C3 (sC3)
sC3 Designed for Increased Catalytic Efficiency, Potency, Better pK Properties
sC3 Depletes Complement More Potently than CVF
sC3 is More Stable in Serum
sC3 Resists Degradation
sC3 Gene Therapy Strategy
sC3 Gene Therapy Sub-Retinal Injections of Viral Particles
sC3 Gene Therapy Coding Sequence and HEK293 Co-Transfection
sC3 Gene Therapy, Vector Design Completed, Lentivirus Synthesized, RPE Cells Infected
sC3 Cascade Intellectual Property
Gallery
What's Hot in Complement 2020-2021
Pipeline
Disease Program
Research Project Codes
Project Phase
Status
Paroxysmal Nocturnal Hemoglobinuria
CB101
Development
Scale-up for IND-Enabling GLP Studies
Retinal Gene Therapy
CB201
Discovery
In Vivo Testing
Neuromyelitis Optica
CB301
Discovery
In Vitro Research
Myasthenia Gravis
CB401
Discovery
In Vitro Research
Renal Disease
CB501
Early Discovery
In Vitro Research
Cancer
CB601
Early Discovery
In Vitro Research
Prodromal Schizophrenia
CB701
Early Discovery
In Vitro Research
Alzheimer's disease
CB801
Early Discovery
In Vitro Research
Amyotrophic Lateral Sclerosis
CB901
Early Discovery
In Vitro Research
*links to detailed page
609-610-3935
edholland@cenoxsys.com
1 Deer Park Dr., Suite D5, Princeton Corporate Plaza, Monmouth Junction, NJ 08852
